FibroGen reduces minimum cash covenant to $18.75M in third amendment to Morgan Stanley financing

KYNTRA BIO, INC.

Third Amendment to Financing Agreement dated July 14, 2025 lowers required U.S. qualified cash from $22.5M to $18.75M.
Amendment with lenders managed by Morgan Stanley Tactical Value and agent Wilmington Trust.
Effective July 14, 2025; no other changes to Financing Agreement terms.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.